Referred to a method of treatment with Pirfenidone comprising: (a) Prevent, Counter, or discontinue use caution with concomitant administration or co Administration of an inhibitor of cytochrome P450 1A2 (CYP1A2) which is an inhibitor of both moderate to Strong cytochrome P450 1A2 (i) (CYP1A2) and (ii) other CYP Enzyme is selected from the group consisting of CYP3A4, CYP2C9, CYP2C19,CYP2B6 and CYP2D6 and \/ or (b) use with caution Pirfenidone in patients receiving inhiidor Strong CYP1A2 or c) used with Caution, a strong inhibitor of CYP1A2 in patients receiving Pirfenidone. This method of treatment with Pirfenidone is useful for the treatment of pulmonary fibrosis, Diabetic Retinopathy, gout, Osteoarthritis, ulcerative colitisREFERIDO A UN METODO DE TRATAMIENTO CON PIRFENIDONA QUE COMPRENDE: A) EVITAR, CONTRAINDICAR, DISCONTINUAR O USAR CON PRECAUCION LA ADMINISTRACION CONCOMITANTE O LA CO-ADMINISTRACION DE UN INHIBIDOR DE CITOCROMO P450 1A2 (CYP1A2) QUE ES UN INHIBIDOR MODERADO A FUERTE DE AMBOS (i) CITOCROMO P450 1A2 (CYP1A2) Y (ii) OTRA ENZIMA CYP SELECCIONADA DEL GRUPO QUE CONSISTE DE CYP3A4, CYP2C9, CYP2C19, CYP2B6 Y/O CYP2D6, O B) USAR CON PRECAUCION LA PIRFENIDONA EN PACIENTES QUE RECIBEN UN INHIIDOR FUERTE DE CYP1A2 O C) USAR CON PRECAUCION DE UN INHIBIDOR FUERTE DE CYP1A2 EN PACIENTES QUE RECIBEN PIRFENIDONA. DICHO METODO DE TRATAMIENTO CON PIRFENIDONA ES UTIL PARA EL TRATAMIENTO DE FIBROSIS PULMONAR, RETINOPATIA DIABETICA, GOTA, OSTEOARTRITIS, COLITIS ULCEROSA
